Less than a tenth of individuals eligible to benefit from obesity jabs like Wegovy are able to get them, states the global health agency as it issues its inaugural guidance on the medications.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for more widespread and fairer availability to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The new guidance affirms that excess weight is a chronic disease that can be managed with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key barriers to widespread availability to the treatments that can aid individuals in losing substantial body mass, says the body.
Skinny Jab Supply Crisis
Despite the present most optimistic scenario, the production of these medications might only reach around 100 million people – fewer than 10% of eligible patients, according to the health organization.
The advice encourages governments and firms to increase access, by approaches including licensing agreements.
Exclusive production rights on a key compound – the core component of a leading brand – is set to lapse in several nations in 2026.
How Obesity Injections Function
The injections imitate a natural hormone to reduce digestion speed, suppress the appetite and increase satiety so users eat less.
Individuals typically begin shedding pounds within a few weeks of beginning the once-weekly jabs.
Evidence indicates patients may see weight return after a year of discontinuing the drug, because their normal food cravings come back.
Being carrying excess weight elevates your risk for developing health problems, like diabetes, heart disease, stroke, and certain cancers.
Obesity impacts people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
